A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours, Published online: 13 March 2018; doi:10.1038/s41416-018-0006-0

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

http://ift.tt/2FCAxGo